Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by retiredcopon Nov 09, 2020 11:35am
117 Views
Post# 31863032

RE:RE:RE:RE:Serology test

RE:RE:RE:RE:Serology test
Actuarial wrote: No one truely care about serology test. As long as we have vaccine, the game is over. Vaccine = lock down. Covid-19 would disppear soon alike SARS. PMN is too late to be in the game, again and again. Don't depend on it. If there is no clinical trial on PMN310, there is no chance SP moving up. It is sadly true.



Covid is going to disappear soon .What rabbit hole do you live in? 

We are just starting to see the real impact of this virus is... the vaccines production is in a frenzy... as much as we want to ... but you cant shorten the time it takes to know if the vaccine is effective.over an extended period of time.. the covid serology test is one of the better ways of answering a number of questions pertaining to the vaccine and its effectiveness. The more vaccines the better the chance.... we are talking billions of doses and in the same picture... billions of tests required... 

.. Dr Cashman in conversaation this summer made two very good points ... 
1- he was worried that the FDA had lowered its threshold on covid vaccines to 50% effectiveness for approval 
2- and that this virus is going to get alot worse this winter 

 
<< Previous
Bullboard Posts
Next >>